Thromboembolism

• 

  Subject Areas on Research

  • 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. 
  • A Bridge to Nowhere? Benefits and Risks for Periprocedural Anticoagulation in Atrial Fibrillation. 
  • A case series describing causes of death in pregnant women with sickle cell disease in a low-resource setting. 
  • A colorimetric assay for releasable plasminogen activator. 
  • A comparison of dabigatran etexilate with warfarin in patients with mechanical heart valves: THE Randomized, phase II study to evaluate the safety and pharmacokinetics of oral dabigatran etexilate in patients after heart valve replacement (RE-ALIGN). 
  • A comparison of thrombolytic therapy with operative revascularization in the initial treatment of acute peripheral arterial ischemia. 
  • A non-experimental study of oral anticoagulation therapy initiation before and after national patient safety goals. 
  • A novel bioresorbable polymer paclitaxel-eluting stent for the treatment of single and multivessel coronary disease: primary results of the COSTAR (Cobalt Chromium Stent With Antiproliferative for Restenosis) II study. 
  • A pharmacogenetic versus a clinical algorithm for warfarin dosing. 
  • A phase II study of estramustine, docetaxel, and exisulind in patients with hormone- refractory prostate cancer: results of cancer and leukemia group B trial 90004. 
  • A prospective study of venous thromboembolism in relation to factor V Leiden and related factors. 
  • Acute and chronic mesenteric ischemia. 
  • Adverse events in the use of HeartMate vented electric and Novacor left ventricular assist devices: comparing apples and oranges. 
  • Amiodarone, anticoagulation, and clinical events in patients with atrial fibrillation: insights from the ARISTOTLE trial. 
  • Anemia is associated with bleeding and mortality, but not stroke, in patients with atrial fibrillation: Insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. 
  • Angiosarcoma of the pericardium presenting as hemorrhagic pleuropericarditis, cardiac tamponade, and thromboembolic phenomena. 
  • Anti-beta(2)-glycoprotein I antibody-mediated inhibition of activated protein C requires binding of beta(2)-glycoprotein I to phospholipids. 
  • Anti-heparin/platelet factor 4 antibody optical density values and the confirmatory procedure in the diagnosis of heparin-induced thrombocytopenia. 
  • Anticoagulants in pregnancy. 
  • Anticoagulation and Antiplatelet Strategies After On-X Mechanical Aortic Valve Replacement. 
  • Anticoagulation therapy and clinical outcomes in patients with recently diagnosed atrial fibrillation: Insights from the ARISTOTLE trial. 
  • Anticoagulation, novel agents, and procedures: can we pardon the interruption? 
  • Anticoagulation. 
  • Antiphospholipid syndrome: laboratory testing and diagnostic strategies. 
  • Antithrombotic Therapy and Cardiovascular Outcomes After Transcatheter Aortic Valve Replacement in Patients With Atrial Fibrillation. 
  • Antithrombotic therapies in patients with prosthetic heart valves: guidelines translated for the clinician. 
  • Antithrombotic therapy after prosthetic cardiac valve implantation: potential novel antithrombotic therapies. 
  • Antithrombotic therapy in atrial fibrillation associated with valvular heart disease: a joint consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, endorsed by the ESC Working Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), South African Heart (SA Heart) Association and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE). 
  • Antithrombotic therapy practices in US hospitals in an era of practice guidelines. 
  • Antithrombotic therapy use and clinical outcomes following thrombo-embolic events in patients with atrial fibrillation: insights from ARISTOTLE. 
  • Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Left Ventricular Hypertrophy: Insights From the ARISTOTLE Trial. 
  • Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationale. 
  • Apixaban in Comparison With Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: Findings From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial. 
  • Apixaban or Warfarin and Aspirin or Placebo After Acute Coronary Syndrome or Percutaneous Coronary Intervention in Patients With Atrial Fibrillation and Prior Stroke: A Post Hoc Analysis From the AUGUSTUS Trial. 
  • Apixaban versus warfarin in patients with atrial fibrillation according to prior warfarin use: results from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial. 
  • Apixaban versus warfarin in patients with atrial fibrillation. 
  • Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. 
  • Association Between Left Atrial Appendage Occlusion and Readmission for Thromboembolism Among Patients With Atrial Fibrillation Undergoing Concomitant Cardiac Surgery. 
  • Association of body weight with efficacy and safety outcomes in phase III randomized controlled trials of direct oral anticoagulants: a systematic review and meta-analysis. 
  • Atrial Fibrillation and Diabetes Mellitus: Can We Modify Stroke Risk Through Glycemic Control? 
  • Autologous endothelial progenitor cell-seeding technology and biocompatibility testing for cardiovascular devices in large animal model. 
  • Bevacizumab and the risk of arterial and venous thromboembolism in patients with metastatic, castration-resistant prostate cancer treated on Cancer and Leukemia Group B (CALGB) 90401 (Alliance). 
  • Bevacizumab in the treatment of metastatic colorectal cancer: safety profile and management of adverse events. 
  • Bilateral adrenal hemorrhage: the unrecognized cause of hemodynamic collapse associated with heparin-induced thrombocytopenia. 
  • Biomarkers of inflammation and risk of cardiovascular events in anticoagulated patients with atrial fibrillation. 
  • Blood Pressure Control and Risk of Stroke or Systemic Embolism in Patients With Atrial Fibrillation: Results From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial. 
  • Blood coagulation and idiopathic thromboembolism among fertile women. 
  • Bridging Anticoagulation in Patients with Atrial Fibrillation. 
  • Bridging Antiplatelet Therapy After Percutaneous Coronary Intervention: JACC Review Topic of the Week. 
  • COVID-19: Thrombosis, thromboinflammation, and anticoagulation considerations. 
  • CT for thromboembolic disease. 
  • Cardioversion of nonrheumatic atrial fibrillation. Reduced thromboembolic complications with 4 weeks of precardioversion anticoagulation are related to atrial thrombus resolution. 
  • Case-control study of thromboembolic events associated with IV immunoglobulin. 
  • Cerebral magnetic resonance findings in asymptomatic patients after atrial fibrillation catheter ablation: cause for alarm or further study? 
  • Changing the Postpartum Care Paradigm. 
  • Chronic Thromboembolic Pulmonary Hypertension: the Bench. 
  • Chronic major-vessel thromboembolic pulmonary hypertension. 
  • Chronic thromboembolic pulmonary hypertension and pulmonary thromboendarterectomy. 
  • Chronic thromboembolic pulmonary hypertension in pediatric patients. 
  • Chronic thromboembolic pulmonary hypertension. 
  • Chronic thromboembolic pulmonary hypertension. 
  • Clinical Outcomes and History of Fall in Patients with Atrial Fibrillation Treated with Oral Anticoagulation: Insights From the ARISTOTLE Trial. 
  • Clinical and laboratory evaluation of the hypercoagulable states. 
  • Clinical and laboratory manifestations of anti-factor V antibodies. 
  • Clinical comparison of St. Jude and porcine aortic valve prostheses. 
  • Clinical consequences of off-label reduced dosing of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: a systematic review and meta-analysis. 
  • Clinical effectiveness of anticoagulation therapy among older patients with heart failure and without atrial fibrillation: findings from the ADHERE registry linked to Medicare claims. 
  • Clinical implications of pulmonary hypertension in mitral stenosis. 
  • Clinical outcomes and management associated with major bleeding in patients with atrial fibrillation treated with apixaban or warfarin: insights from the ARISTOTLE trial. 
  • Clinical outcomes of cardiac surgery patients undergoing therapeutic plasma exchange for heparin-induced thrombocytopenia. 
  • Clinical outcomes of patients with diabetes and atrial fibrillation treated with apixaban: results from the ARISTOTLE trial. 
  • Clinical outcomes with unfractionated heparin or low-molecular-weight heparin as bridging therapy in patients on long-term oral anticoagulants: the REGIMEN registry. 
  • Clinical pharmacology considerations for children supported with ventricular assist devices. 
  • Coagulation Abnormalities in Heart Failure: Pathophysiology and Therapeutic Implications. 
  • Coagulation and fibrinolytic protein kinetics in cardiopulmonary bypass. 
  • Coagulopathy does not fully protect hospitalized cirrhosis patients from peripheral venous thromboembolism. 
  • Coagulopathy of Coronavirus Disease 2019. 
  • Combined use of warfarin and oral P2Y12 inhibitors in patients with atrial fibrillation and acute coronary syndrome. 
  • Comment on: editorial by Husted et al. "Non-vitamin K antagonist oral anticoagulants (NOACs): no longer new or novel". (Thromb Haemost 2014; 111: 781-782). 
  • Comparison of anticoagulation regimens after Carpentier-Edwards aortic or mitral valve replacement. 
  • Complications of low-dose heparin prophylaxis in gynecologic oncology surgery. 
  • Contemporary Trends in Oral Anticoagulant Prescription in Atrial Fibrillation Patients at Low to Moderate Risk of Stroke After Guideline-Recommended Change in Use of the CHADS2 to the CHA2DS2-VASc Score for Thromboembolic Risk Assessment: Analysis From the National Cardiovascular Data Registry's Outpatient Practice Innovation and Clinical Excellence Atrial Fibrillation Registry. 
  • Continuing anticoagulation following venous thromboembolism. 
  • Contribution of bleeding and thromboembolic events to in-hospital mortality among patients with thrombocytopenia treated with heparin. 
  • Correlation of left ventricular diastolic filling characteristics with right ventricular overload and pulmonary artery pressure in chronic thromboembolic pulmonary hypertension. 
  • D-dimer and risk of thromboembolic and bleeding events in patients with atrial fibrillation--observations from the ARISTOTLE trial. 
  • Dabigatran for periprocedural anticoagulation following radiofrequency ablation for atrial fibrillation: a meta-analysis of observational studies. 
  • Dabigatran versus warfarin in patients with mechanical heart valves. 
  • Decreased platelet aggregation, increased bleeding time and resistance to thromboembolism in P2Y1-deficient mice. 
  • Deep venous thrombosis and pulmonary embolism. 
  • Detection of antibody-mediated reduction of annexin A5 anticoagulant activity in plasmas of patients with the antiphospholipid syndrome. 
  • Determinants of 15-year outcome with 1,119 standard Carpentier-Edwards porcine valves. 
  • Direct oral anticoagulants: new drugs and new concepts. 
  • Distal microcirculatory protection during percutaneous coronary intervention in acute ST-segment elevation myocardial infarction: a randomized controlled trial. 
  • Do anticoagulation management services improve care? Implications of the Managing Anticoagulation Services Trial. 
  • Documentation of study medication dispensing in a prospective large randomized clinical trial: experiences from the ARISTOTLE Trial. 
  • Does early detection of atrial fibrillation reduce the risk of thromboembolic events? Rationale and design of the Heartline study. 
  • Dyslipidemia and Risk of Cardiovascular Events in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Therapy: Insights From the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) Trial. 
  • Early anticoagulation of bioprosthetic aortic valves in older patients: results from the Society of Thoracic Surgeons Adult Cardiac Surgery National Database. 
  • Early cardioversion of atrial fibrillation facilitated by transesophageal echocardiography: short-term safety and impact on maintenance of sinus rhythm at 1 year. 
  • Echocardiographic Risk Factors for Stroke and Outcomes in Patients With Atrial Fibrillation Anticoagulated With Apixaban or Warfarin. 
  • Echocardiography-derived tricuspid regurgitant jet velocity is an important marker for the progression of sickle-cell disease. 
  • Effect of Antifibrinolytic Therapy on Complications, Thromboembolic Events, Blood Product Utilization, and Fusion in Adult Spinal Deformity Surgery. 
  • Effect of Mailing Educational Material to Patients With Atrial Fibrillation and Their Clinicians on Use of Oral Anticoagulants: A Randomized Clinical Trial. 
  • Effects of apixaban compared with warfarin as gain in event-free time - a novel assessment of the results of the ARISTOTLE trial. 
  • Efficacy and Safety of Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Extremes in Body Weight. 
  • Efficacy and Safety of Apixaban Versus Warfarin in Patients with Atrial Fibrillation and a History of Cancer: Insights from the ARISTOTLE Trial. 
  • Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants After Cardioversion for Nonvalvular Atrial Fibrillation. 
  • Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation. 
  • Efficacy and safety of apixaban in patients after cardioversion for atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation). 
  • Efficacy and safety of aspirin combined with warfarin after acute coronary syndrome : A meta-analysis. 
  • Efficacy and safety of early versus late initiation of warfarin during heparin therapy in acute thromboembolism. 
  • Efficacy and safety of low intensity vitamin K antagonists in Western and East-Asian patients with left-sided mechanical heart valves. 
  • Efficacy and safety of low molecular weight heparin (ardeparin sodium) compared to warfarin for the prevention of venous thromboembolism after total knee replacement surgery: a double-blind, dose-ranging study. Ardeparin Arthroplasty Study Group. 
  • Embolic and Other Adverse Outcomes in Symptomatic Versus Asymptomatic Patients With Atrial Fibrillation (from the ORBIT-AF Registry). 
  • Embolic strokes of undetermined source: the case for a new clinical construct. 
  • Endothelial Injury in COVID-19 and Acute Infections: Putting the Pieces of the Puzzle Together. 
  • Ethnic differences in thromboprophylaxis for COVID-19 patients: should they be considered? 
  • Evaluating Discrimination of Risk Prediction Models: The C Statistic. 
  • Evaluation and management of the atrial fibrillation patient: a report from the Society of Cardiovascular Patient Care. 
  • Excess factor VIII and hypercoagulability. 
  • Factor V Leiden mutation and thromboembolism risk in women receiving adjuvant tamoxifen for breast cancer. 
  • Family history of atrial fibrillation is associated with earlier-onset and more symptomatic atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. 
  • Fatal fungal infection following open-heart surgery. 
  • Fibrinolytic response and oral contraceptive associated thromboembolism. 
  • Foreword: The Prevention and Management of Thrombosis in Obstetrics and Gynecology. 
  • Gender Differences in Associations Between Intraprocedural Thrombotic Events During Percutaneous Coronary Intervention and Adverse Outcomes. 
  • Gene-expression patterns predict phenotypes of immune-mediated thrombosis. 
  • Growth differentiation factor 15, a marker of oxidative stress and inflammation, for risk assessment in patients with atrial fibrillation: insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. 
  • Hemostatic abnormalities in patients with congestive heart failure: diagnostic significance and clinical challenge. 
  • Heparin coating of vascular prostheses reduces thromboemboli. 
  • Heparin-Induced Thrombocytopenia: A Review for Cardiac Anesthesiologists and Intensivists. 
  • Heparin-induced decrease in circulating antithrombin-III. 
  • Heparin-induced thrombocytopenia in left ventricular assist device bridge-to-transplant patients. 
  • High-sensitivity troponin I for risk assessment in patients with atrial fibrillation: insights from the Apixaban for Reduction in Stroke and other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. 
  • History of bleeding and outcomes with apixaban versus warfarin in patients with atrial fibrillation in the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial. 
  • Hypercoagulable states in cardiovascular disease. 
  • Impact of Atrial Fibrillation on In-Hospital Mortality and Thromboembolic Complications after Left Ventricular Assist Device Implantation. 
  • Impact of Non-Vitamin K Antagonist Oral Anticoagulants From a Basic Science Perspective. 
  • In vivo evaluations of a new thromboresistant polyurethane for artificial heart blood pumps. 
  • Independent predictors of stroke in patients with atrial fibrillation: a systematic review. 
  • Indications for Left Atrial Appendage Occlusion in the United States and Associated In-Hospital Outcomes: Results From the NCDR LAAO Registry. 
  • Inhibition of mTOR attenuates store-operated Ca2+ entry in cells from endarterectomized tissues of patients with chronic thromboembolic pulmonary hypertension. 
  • Insulin Therapy and Stroke Risk in Patients With Diabetes and Atrial Fibrillation: Guilty by Association? 
  • Interruption of non-vitamin K antagonist anticoagulants in patients undergoing planned invasive procedures: how long is long enough? 
  • Interventions for Preventing Thromboembolic Events in Patients With Atrial Fibrillation: A Systematic Review. 
  • Intracoronary bolus administration of eptifibatide during percutaneous coronary stenting for non ST elevation myocardial infarction and unstable angina. 
  • Invited commentary. 
  • Is bleeding a necessary evil? The inherent risk of antithrombotic pharmacotherapy used for stroke prevention in atrial fibrillation. 
  • Ischemic and Bleeding Outcomes in Patients With Atrial Fibrillation and Contraindications to Oral Anticoagulation. 
  • Laboratory diagnosis of the lupus anticoagulant. 
  • Left atrial appendage occlusion: rationale, evidence, devices, and patient selection. 
  • Long-term Thromboembolic Risk in Patients With Postoperative Atrial Fibrillation After Coronary Artery Bypass Graft Surgery and Patients With Nonvalvular Atrial Fibrillation. 
  • Low dose heparin therapy: in vitro verification of antithrombotic effect. 
  • Low thromboembolism and pump thrombosis with the HeartMate II left ventricular assist device: analysis of outpatient anti-coagulation. 
  • Low-Dose vs Standard Warfarin After Mechanical Mitral Valve Replacement: A Randomized Trial. 
  • Lower versus Standard INR Targets in Atrial Fibrillation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. 
  • Lupus anticoagulant, heparin use, and thrombocytopenia in patients with chronic thromboembolic pulmonary hypertension: a preliminary report. 
  • Maintenance of warfarin therapy at an anticoagulation clinic. 
  • Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: The ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation): Predictors, Characteristics, and Clinical Outcomes. 
  • Management of Major Bleeding in Patients With Atrial Fibrillation Treated With Non-Vitamin K Antagonist Oral Anticoagulants Compared With Warfarin in Clinical Practice (from Phase II of the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation [ORBIT-AF II]). 
  • Managing thrombosis and cardiovascular complications of COVID-19: answering the questions in COVID-19-associated coagulopathy. 
  • Medically Ill hospitalized Patients for COVID-19 THrombosis Extended ProphyLaxis with rivaroxaban ThErapy: Rationale and Design of the MICHELLE Trial. 
  • Meta-Analysis of Genotype-Guided Versus Standard Dosing of Vitamin K Antagonists. 
  • Metabolism of norethynodrel in thrombophlebitic-thromboembolic subjects. 
  • Mobile intracardiac calcinosis: risk of thromboembolism in patients with haemodialysed end stage renal disease. 
  • Model predictions of deformation, embolization and permeability of partially obstructive blood clots under variable shear flow. 
  • Monitoring warfarin therapy in patients with lupus anticoagulants. 
  • Morbidity following lower extremity fractures in men with spinal cord injury. 
  • Mortality after total hip and knee arthroplasty in a medium-volume university practice. 
  • Mortality and rate of stroke or embolism in atrial fibrillation during long-term follow-up in the embolism in left atrial thrombi (ELAT) study. 
  • Multimodal prophylaxis for THA with mechanical compression. 
  • Multiplex protein screening of biomarkers associated with major bleeding in patients with atrial fibrillation treated with oral anticoagulation. 
  • New classes of anticoagulation and antiplatelet agents: preprocedure management and safety guidelines for imaging-guided intervention. 
  • New concepts in orthopaedic thromboprophylaxis. 
  • Newer oral anticoagulants should be used as first-line agents to prevent thromboembolism in patients with atrial fibrillation and risk factors for stroke or thromboembolism. 
  • Non-major bleeding with apixaban versus warfarin in patients with atrial fibrillation. 
  • Novel Antithrombotic Agents in Pregnancy Anticoagulants and Antiplatelet Agents. 
  • Obesity in women: anaesthetic implications for peri-operative and peripartum management. 
  • Oral contraceptives and thromboembolic disease. 
  • Oral factor Xa inhibitors for the prevention of stroke in atrial fibrillation. 
  • Osteoporotic fractures in older adults. 
  • Outcomes Associated With Familial Versus Nonfamilial Atrial Fibrillation: A Matched Nationwide Cohort Study. 
  • Outcomes associated with warfarin use in older patients with heart failure and atrial fibrillation and a cardiovascular implantable electronic device: findings from the ADHERE registry linked to Medicare claims. 
  • Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation). 
  • Outcomes of surgical revascularization for lower extremity arterial thromboembolism in patients with advanced malignancy. 
  • Pathophysiology of bleeding and clotting in the cardiac surgery patient: from vascular endothelium to circulatory assist device surface. 
  • Patterns of anticoagulation following bioprosthetic valve implantation: observations from ANSWER. 
  • Patterns of infarction in hemodynamic failure. 
  • Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation. 
  • Perioperative management of patients on chronic antithrombotic therapy. 
  • Periprocedural antiplatelet therapy: recommendations for standardized reporting in patients on antiplatelet therapy: communication from the SSC of the ISTH. 
  • Periprocedural antithrombotic and bridging therapy: recommendations for standardized reporting in patients with arterial indications for chronic oral anticoagulant therapy. 
  • Periprocedural management of patients receiving a vitamin K antagonist or a direct oral anticoagulant requiring an elective procedure or surgery. 
  • Polypharmacy and effects of apixaban versus warfarin in patients with atrial fibrillation: post hoc analysis of the ARISTOTLE trial. 
  • Post-operative heparin may not be required for transitioning patients with a HeartMate II left ventricular assist system to long-term warfarin therapy. 
  • Postoperative and Nonvalvular Atrial Fibrillation-Not So Different After All. 
  • Practice bulletin no. 123: thromboembolism in pregnancy. 
  • Prasugrel, a third generation thienopyridine and potent platelet inhibitor. 
  • Pre-operative homocysteine levels and morbidity and mortality following cardiac surgery. 
  • Predicting Thromboembolic and Bleeding Event Risk in Patients with Non-Valvular Atrial Fibrillation: A Systematic Review. 
  • Predictive factors of thromboembolic events in patients undergoing Roux-en-Y gastric bypass. 
  • Predictors of Warfarin Time in Therapeutic Range after Continuous-Flow Left Ventricular Assist Device. 
  • Premature permanent discontinuation of apixaban or warfarin in patients with atrial fibrillation. 
  • Prestroke and Poststroke Antithrombotic Therapy in Patients With Atrial Fibrillation: Results From a Nationwide Cohort. 
  • Prevalence of factor V G1691A (Leiden), prothrombin G20210A, and methylene tetrahydrofolate reductase C677T thrombophilic mutations in children with inflammatory bowel disease. 
  • Prevalence of heparin-associated antibodies without thrombosis in patients undergoing cardiopulmonary bypass surgery. 
  • Prevalence of residual left atrial thrombi among patients with acute thromboembolism and newly recognized atrial fibrillation. 
  • Prevention and Management of Thromboembolism in Pregnancy When Heparins Are Not an Option. 
  • Prophylaxis for thromboembolic disease: recommendations from the American College of Chest Physicians--are they appropriate for orthopaedic surgery? 
  • Prothrombin Complex Concentrates for Bleeding in the Perioperative Setting. 
  • Protocolized hemostatic factor use in major thoracic aortic surgery. 
  • Pulmonary hypertension and nitric oxide depletion in sickle cell disease. 
  • Putting the vascular back into cardiovascular research: ST-segment-elevation myocardial infarction as a blueprint for improving care in patients with acute limb ischemia. 
  • RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome. 
  • Randomized double-blind placebo-controlled trial of cisplatin and etoposide plus megestrol acetate/placebo in extensive-stage small-cell lung cancer: a North Central Cancer Treatment Group study. 
  • Rate versus rhythm control for management of atrial fibrillation in clinical practice: results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. 
  • Rationale and design of PROACT Xa: A randomized, multicenter, open-label, clinical trial to evaluate the efficacy and safety of apixaban versus warfarin in patients with a mechanical On-X Aortic Heart Valve. 
  • Rationale and design of the Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation (ARTESiA) trial. 
  • Reasons for warfarin discontinuation in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). 
  • Reduced anticoagulation after mechanical aortic valve replacement: interim results from the prospective randomized on-X valve anticoagulation clinical trial randomized Food and Drug Administration investigational device exemption trial. 
  • Reducing the risk of oral contraceptive-induced thrombosis. 
  • Reducing thrombotic complications in the perioperative setting: an update on heparin-induced thrombocytopenia. 
  • Relation of Risk of Stroke in Patients With Atrial Fibrillation to Body Mass Index (from Patients Treated With Rivaroxaban and Warfarin in the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation Trial). 
  • Response to letter regarding article, "Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation". 
  • Restarting Therapeutic Anticoagulation After Elective Craniotomy for Patients with Chronic Atrial Fibrillation: A Review of the Literature. 
  • Rhythm control in atrial fibrillation. 
  • Risk assessment in atrial fibrillation: not all factors are created equal. 
  • Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study. 
  • Risk of thromboembolism in cisplatin versus carboplatin-treated patients with lung cancer. 
  • Risk of thromboembolism in heart failure: an analysis from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). 
  • Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry. 
  • Risk stratification for stroke in atrial fibrillation: a critique. 
  • Routine bivalirudin use in percutaneous carotid interventions. 
  • SCAI/HRS expert consensus statement on transcatheter left atrial appendage closure. 
  • Safety and Efficacy of Rivaroxaban in Patients With Cardiac Implantable Electronic Devices: Observations From the ROCKET AF Trial. 
  • Safety and efficacy of tirofiban in stent-assisted coil embolization of intracranial aneurysms. 
  • Safety of bevacizumab in patients with metastatic breast cancer. 
  • Safety of recombinant activated factor VII in randomized clinical trials. 
  • Safety of tirofiban and dual antiplatelet therapy in treating intracranial aneurysms. 
  • Safety of warfarin dosing in the intensive care unit following the Fontan procedure. 
  • Screening of Multiple Biomarkers Associated With Ischemic Stroke in Atrial Fibrillation. 
  • Searching for Atrial Fibrillation Poststroke: A White Paper of the AF-SCREEN International Collaboration. 
  • Self-monitoring of oral anticoagulation: systematic review and meta-analysis of individual patient data. 
  • Stroke and thromboembolic events in men with prostate cancer treated with definitive radiation therapy with or without androgen deprivation therapy. 
  • Ten-year results with the St. Jude Medical prosthesis. 
  • Thalidomide has limited single-agent activity in relapsed or refractory indolent non-Hodgkin lymphomas: a phase II trial of the Cancer and Leukemia Group B. 
  • The Worcester Venous Thromboembolism study: a population-based study of the clinical epidemiology of venous thromboembolism. 
  • The association of anti-platelet factor 4/heparin antibodies with early and delayed thromboembolism after cardiac surgery. 
  • The atrial FibriLlatiOn real World management registry in the Middle East and Africa: design and rationale. 
  • The long and winding road to warfarin pharmacogenetic testing. 
  • The management of Cesarean delivery in a parturient with paroxysmal nocturnal hemoglobinuria complicated by severe preeclampsia. 
  • The management of pulmonary hypertension secondary to chronic thromboembolic disease. 
  • The preoperative use of erythropoietin stimulating proteins prior to radical prostatectomy is not associated with increased cardiovascular or thromboembolic morbidity or mortality. 
  • The preventability of ventilator-associated events. The CDC Prevention Epicenters Wake Up and Breathe Collaborative. 
  • The risk of thromboembolic events with early intravenous 2- and 4-g bolus dosing of tranexamic acid compared to placebo in patients with severe traumatic bleeding: A secondary analysis of a randomized, double-blind, placebo-controlled, single-center trial. 
  • The use of a temporary vena caval interruption device in high-risk trauma patients unable to receive standard venous thromboembolism prophylaxis. 
  • Three-factor prothrombin complex concentrates for refractory bleeding after cardiovascular surgery within an algorithmic approach to haemostasis. 
  • Thromboembolic Events with Enterprise Versus Pipeline: Porcine In Vivo Experiment. 
  • Thromboembolic complications after Fontan operations. 
  • Thromboembolic complications after Neuroform stent-assisted treatment of cerebral aneurysms: the Duke Cerebrovascular Center experience in 235 patients with 274 stents. 
  • Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand. 
  • Thromboembolism after WATCHMANTM in a clopidogrel non-responder: A case for concern? 
  • Thromboembolism after negative TEE. 
  • Thromboembolism after total knee arthroplasty: intermittent pneumatic compression and aspirin prophylaxis. 
  • Thromboembolism and antithrombotic therapy in patients with heart failure in sinus rhythm: current status and future directions. 
  • Thromboembolism and bleeding in bladder cancer. 
  • Thromboembolism in hospitalized neutropenic cancer patients. 
  • Thromboembolism in pregnancy: recurrence and its prevention. 
  • Thromboembolism in pregnancy: recurrence risks, prevention and management. 
  • Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. 
  • Thrombogenesis in atrial fibrillation contributing mechanisms and natural history. 
  • Thromboprophylaxis with fondaparinux in high-risk postoperative patients with renal insufficiency. 
  • Thrombosis during pregnancy and the postpartum period. 
  • Thrombosis, thrombophilia, and thromboprophylaxis in pregnancy. 
  • Thrombus on the inflow cannula of the HeartWare HVAD: an update. 
  • Throwing out the thromboemboli. 
  • To bridge or not to bridge: these are the questions. 
  • Transesophageal echocardiographically facilitated early cardioversion from atrial fibrillation using short-term anticoagulation: final results of a prospective 4.5-year study. 
  • Transesophageal echocardiography and atrial fibrillation: added value or expensive toy? 
  • Transesophageal echocardiography: useful tool or expensive toy? 
  • Treatment of anemia with darbepoetin alfa in systolic heart failure. 
  • Two mechanical devices for prophylaxis of thromboembolism after total knee arthroplasty. A prospective, randomised study. 
  • Updated European Heart Rhythm Association practical guide on the use of non-vitamin-K antagonist anticoagulants in patients with non-valvular atrial fibrillation: Executive summary. 
  • Utility of right ventricular Tei index in the noninvasive evaluation of chronic thromboembolic pulmonary hypertension before and after pulmonary thromboendarterectomy. 
  • Validation of the obesity surgery mortality risk score in a multicenter study proves it stratifies mortality risk in patients undergoing gastric bypass for morbid obesity. 
  • Variation in warfarin thromboprophylaxis after mitral valve repair: does equipoise exist and is a randomized trial warranted? 
  • Vascular plasminogen activator levels and thromboembolic disease in patients with gynecologic malignancies. 
  • Venous and arterial thromboembolic disease in women using oral contraceptives. 
  • Venous thromboembolic disease. Clinical practice guidelines in oncology. 
  • Venous thromboembolic disease. NCCN. Clinical practice guidelines in oncology. 
  • Venous thromboembolism during pregnancy and the postpartum period: incidence, risk factors, and mortality. 
  • Warfarin and Aspirin Versus Warfarin Alone for Prevention of Embolic Events in Patients with a HeartMate II Left Ventricular Assist Device. 
  • When the body and appendage of the left atrium disagree: "Focal" atrial fibrillation-implications for atrial thrombus formation and risk of thromboembolism. 
  • [Antiplatelet and anticoagulant therapy for stroke prevention in patients with non-valvular atrial fibrillation: evidence based strategies and new developments]. 
• 

  Keywords of People

  • Alexander, John Hunter Peel, Professor of Medicine, Medicine, Cardiology
  • Granger, Christopher Bull, Professor of Medicine, School of Nursing
  • O'Connor, Christopher Michael, Adjunct Professor in the Department of Medicine, Medicine, Clinical Pharmacology